bioRxivImmunologyPreprint
Rab5 Overcomes CAR T Cell Dysfunction Induced by Tumor-Mediated CAR Capture
Meidi GuiD, Edmund J. CarvalhoiD, Kaitlin A. ReadiD, David Padron NardoiD, James L. RileyiD
Abstract
Continuous interaction between chimeric antigen receptor (CAR) T cell (CART) and tumors often result in CART dysfunction and tumor escape. We observed that tumors can take up CAR molecules, leaving CARTs without surface-expressed CARs and thus unable to kill tumors after prolonged exposure. Overexpression of Rab5 resulted in augmented clathrin-independent endocytosis, preventing loss of surface-expressed CARs, and enhanced CART activity. Interestingly, we observed membrane protrusions on the CART cell surface which disappeared after multiple tumor challenges. Rab5 maintained these protrusions after repeated tumor engagements and their presence correlated with effective tumor clearance, suggesting a link between endocytosis, membrane protrusions, and cytolytic activity. In vivo, Rab5-expressing CARTs demonstrated improved activity and were able to clear an otherwise refractory mesothelin-expressing solid cancer in humanized mice by maintaining CAR surface expression within the tumor. Thus, pairing Rab5 with CAR expression could improve the clinical efficacy of CART therapy. Highlights O_LI"CAR-jacking" occurs when surface CAR is internalized by target tumor cells. C_LIO_LIRab5 overexpression prevents "CAR-jacking" and enhances CART function. C_LIO_LIRab5 promotes CAR endocytic recycling and maintains membrane protrusions. C_LIO_LIRab5-expressing CARTs exhibit enhanced therapeutic efficacy against solid tumors. C_LI
- organism: mouse
- assay: flow cytometry
- research focus: drug response / drug discovery
- approach: genetic perturbation / CRISPR
- Citations
- 3
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- NKTR-255, a polymer-conjugated IL-15, synergizes with CAR-T cell therapy to activate endogenous anti-tumor immunity and improve tumor control
W. Sam Nutt, Mitchell G. Kluesner, … Shivani Srivastava·bioRxiv·Dec 15, 2025
- CTLA-4 tail fusion enhances CAR-T anti-tumor immunity
- Hyaluronidase unlocks sequestered CEACAM5 and improves CAR T-cell therapy in colorectal cancer
Debasis Banik, Christopher J. Ward, … David Klenerman·Advanced SciencePeer-reviewed·Jan 22, 2026
- DR5 CAR-T cells target solid tumors and suppress MDSCs with minimal toxicity
Huaishan Wang, Shujing Liu, … Xiaowei Xu·bioRxiv·Jun 9, 2025
- Fast receptor-antigen dissociation kinetics promote CAR-T cell tumor infiltration, functional fitness, and antitumor efficacy in solid tumors
Rui Mao, Huidong Shi, … Yukai He·bioRxiv·Oct 12, 2026
- Preventing trogocytosis by cathepsin B inhibition augments CAR T cell function
Kenneth A. Dietze, Kiet Nguyen, … Tim Luetkens·Signal Transduction and Targeted TherapyPeer-reviewed·Apr 22, 2026